You do know RAP has hired a new VP who has extensive commercialisation experience, the plan is to commercialise ResAppDx through telehealth as only RAP can provide this service for them, then doctor in clinic will know about ResAppDx and be "forced" to use the technology otherwise loss patient for these respiratory consultation. IMO, the pps has currently been been extremely oversold with the sell down on big volume on news already known to the market......
RAP Price at posting:
5.8¢ Sentiment: Buy Disclosure: Held